Skip to content

Partnerships

ALX Oncology partners with leading pharmaceutical and biotechnology companies, as well as thought-leading physicians and academic institutions, to explore the full potential of our pipeline in a wide range of oncology indications to improve outcomes for patients.

Current ALX Oncology Clinical Trial Partners

Jazz Pharmaceuticals
Quantum Leap Healthcare Collaborative
Sanofi
Lilly
Merck

ALX Oncology retains worldwide rights to evorpacept in all indications.

  • Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
  • Merck supplies KEYTRUDA® for ALX Oncology’s ASPEN-03 and ASPEN-04 programs
  • Jazz Pharmaceuticals conducts and sponsors zanidatamab clinical trial, ALX Oncology supplies evorpacept
  • Quantum Leap Healthcare Collaborative conducts and sponsors I-SPY clinical trial, ALX Oncology supplies evorpacept
  • Sanofi conducts and sponsors SARCLISA® clinical trial, ALX Oncology supplies evorpacept

We are continuously evaluating strategic relationships and combination approaches that enable evorpacept to be studied in the broadest set of indications possible.

Interested in connecting about a potential partnership? Please visit the Contact page and submit an inquiry.